Esperion Therapeutics (ESPR) Gross Margin (2019 - 2026)
Esperion Therapeutics (ESPR) posted Gross Margin of 56.84% for Q1 2026, up 7.84% on a QoQ basis from 52.71% in Q3 2025, and up 536.0% year-over-year from 8.94% in Q1 2025.
Esperion Therapeutics (ESPR) Gross Margin (2019 - 2026) Analysis & Trends
Esperion Therapeutics' Gross Margin history runs 8 years deep, the most recent figure standing at 56.84% for Q1 2026.
- Quarterly Gross Margin rose 536.0% year-over-year to 56.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42.76% (down 2254.0% YoY) and the FY2024 annual result came in at 79.36%, up 1655.0% from the prior year.
- Gross Margin was 56.84% for Q1 2026 at Esperion Therapeutics, up from 52.71% in the prior quarter.
- Across five years, Gross Margin topped out at 92.69% in Q1 2024 and bottomed at 51.3% in Q2 2022.
- A 5-year average of 64.71% and a median of 63.7% in 2023 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin plunged 4428 bps — and 2024, when it surged 4058 bps.
- Esperion Therapeutics' Gross Margin stood at 77.89% in 2022, then decreased by 17 bps to 64.49% in 2023, then decreased by 2 bps to 62.91% in 2024, then declined by 16 bps to 52.71% in 2025, then increased by 8 bps to 56.84% in 2026.
- Business Quant data shows ESPR's Gross Margin at 56.84% in Q1 2026, 52.71% in Q3 2025, and 65.35% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 56.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.84% |
| Sep 30, 2025 | 52.71% |
| Jun 30, 2025 | 65.35% |
| Mar 31, 2025 | 51.48% |
| Dec 31, 2024 | 62.91% |
| Sep 30, 2024 | 66.52% |
| Jun 30, 2024 | 78.86% |
| Mar 31, 2024 | 92.69% |
| Dec 31, 2023 | 64.49% |
| Sep 30, 2023 | 60.62% |
| Jun 30, 2023 | 73.68% |
| Mar 31, 2023 | 52.11% |
| Dec 31, 2022 | 77.89% |
| Sep 30, 2022 | 65.72% |
| Jun 30, 2022 | 51.30% |
| Mar 31, 2022 | 62.17% |
| Dec 31, 2021 | 67.05% |
| Sep 30, 2021 | 61.43% |
| Jun 30, 2021 | 95.57% |
| Mar 31, 2021 | 77.64% |